Recent Posts

Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer

GENEVA, Dec. 14, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies …

Read More »

Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Investigational Agent SEP-363856 for the Treatment of Schizophrenia

MARLBOROUGH, Mass. & PARAMUS, N.J.–(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc.(PsychoGenics), today announced that positive results …

Read More »